Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2003

View Archived Issues

Enrollment complete in phase III trial of Vivitrex in alcohol dependence

GOT trial studies methods for achieving glycemic control in diabetes

AstraZeneca seeks approval for Nexium in NSAID-associated upper GI symptoms

Zymar approved for bacterial conjunctivitis

Regeneron announces positive preliminary phase III results with Axokine

Dual CCR3 modulators/H1 antagonists and their use reported by AstraZeneca

Novel antibacterial/antiinflammatory indolicidin-derived peptides

Leo Pharma presents novel TNF-alpha and IL-1beta production inhibitors

New GABA-A modulators for anxiety and convulsions under study at Merck

Alpha7 nicotinic acetylcholine receptor agonists presented by Pharmacia

Novel NPY antagonists in Banyu development pipeline

Yissum researchers prepare and test new DNA-damaging platinum complexes

Imidazole cell adhesion inhibitors discovered by Sankyo team

Oral zebularine reactivates silenced genes, inhibits DNA methylation

Takeda plans two trials of Actos in heart disease

NCX-1020 enters clinical development

Ganite sNDA filing completed

Pennsaid approved in Canada

Initiation of first of two expanded phase II trials of GVAX lung cancer vaccine

Chimeric peptides show high potency in CHF in preclinical studies

Oxford BioMedica cleared to begin phase II trial of TroVax in colorectal cancer

Phase III program to assess fondaparinux in acute coronary syndromes

Statistically significant improvement in FSAD in Alista at-home study

Characterization of new CDK1/CDK2 inhibitor

FAUC-312 identified as potent and selective partial agonist at D4 receptors

Orally active triazole inhibitors of TNF-alpha production designed by P&G

Glutamate antagonists with selectivity for the ionotropic GluR5 receptor under study at NeuroSearch

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.